Endoscopic evaluation and histological findings in graft-versus-host disease

Antonio Velasco-Guardado1, Lucía López-Corral2, Alberto Álvarez-Delgado1, Teresa Flores-Corral1, Fernando Geijo-Martínez3, Dolores Caballero-Barrígón2 and Antonio Rodríguez-Pérez1

Departments of 1Gastroenterology, 2Hematology, and 3Pathology. Hospital Universitario de Salamanca. Salamanca, Spain

ABSTRACT

Background: the gastrointestinal (GI) tract is the major target site of the graft-versus-host disease (GVHD). Diagnosis is based on endoscopic and histological findings.

Material and methods: we performed a retrospective study from January 1st, 1990 to December 31st, 2008 on 338 upper gastrointestinal endoscopies (gastroscopies) performed to 197 patients that underwent an allogeneic transplant with clinical suspicion of GI-GVHD.

Results: endoscopic findings to the diagnosis of GVHD have a sensitivity (S) of 34%, specificity levels (SP) of 65%, a positive predictive value (PPV) of 73% and a negative predictive value (NPV) of 48%. The histological study of the endoscopic biopsies has a global sensibility of 85.6% SP = 34.6% PPV = 64.2% and NPV = 63.7%. Histological grade was correlated with the clinical grade of acute GVHD (p = 0.018).

Conclusion: upper gastrointestinal endoscopy is useful for the diagnosis of GVHD, as it allows biopsies that can ultimately lead to the diagnosis, but with limited accuracy because the histological findings have low sensitivity and specificity, while the endoscopic findings are generally nonspecific.

Key words: Graft versus host disease (GVHD). Endoscopy. Histology.

INTRODUCTION

Allogeneic stem cell transplant is the election treatment in patients with haematological malignant diseases. Activity has increased in the last years mainly due to the higher age of patients (up to 65 years), as well as to the existence of a higher number of unrelated donors (> 13 millions); moreover, cord blood is now considered a suitable source of stem cells for adult patients. Graft-versus-host disease (GVHD) is the most important complication after allogeneic transplant and is associated with morbidity and mortality (1). Gastrointestinal acute GVHD presents as nausea, anorexia, vomiting, diarrhea, abdominal pain, hemorrhage and ileus and carries a > 80% risk of mortality in severe forms (grade III-IV) and do not respond to first line therapy (2). Acute GVHD is defined when it appears during the first 100 days (3).

Chronic GVHD appears after 100 days and is the most common cause of death other than disease after hematopietic stem cell transplantation (HSCT) in this period (4). Prior acute GVHD is the most important risk factor for developing chronic GVHD (5).

Due to the frequency of gastrointestinal symptoms during the first 100 days after HSCT more than 50% of the patients will be referred for an endoscopic evaluation of the enteric tract. Differential diagnosis between GVHD and other conditions such as toxicity from chemotherapy or radiotherapy, drug-related side-effects, bacterial, viral, parasitical or fungal infections should be performed (6,7). Endoscopic findings in stomach and duodenum examinations in GVHD may vary between normal mucosa and several unspecific signs such as edema, erythema, frank ulcers and erosion of the mucosa (8).

Histological findings, regardless of the biopsied area, include apoptosis of crypt epithelial cells, destruction of the crypts and variable infiltration of lymphocytes in the epithelium and the lamina propria (6,9). In view of the endoscopic findings, the unspecific symptoms of the patients...
and the significant side-effects of the immunosuppressants used in GVHD therapy, a histological confirmation is required before starting with the treatment (10,11).

Early detection and definitive diagnosis of GVHD are essentials for successful treatment as it can help prevent irreversible organ damage and improve survival.

Unfortunately, the diagnosis of GVHD can be difficult to establish because of the nonspecific nature of associated symptoms, and it requires excluding other diagnoses such as infection, drug effects, malignancies and residual post-inflammatory damage and usually causes a diagnostic challenge to the hematologist. That is the reason why involvement of multidisciplinary team, including gastroenterologists, is critical.

MATERIAL AND METHODS

We performed a retrospective study in all the patients who received an allogeneic HSCT in the University Hospital of Salamanca from January 1, 1990 to December 31, 2008, and who were referred to our Department for an upper gastrointestinal endoscopy due to GVHD suspicion. The endoscopic findings of these explorations were retrospectively compiled, as well as the histological findings of the biopsies (three biopsies at least) performed during the procedure. The stain used was standard hematoxylin and eosin. The presence of apoptotic bodies in the biopsy specimen (minimum criterion), crypt abscesses, and/or destruction of glands were considered criteria for a diagnosis of acute or chronic GVHD, after ruling out other causes that also could induce these findings, such as drug-related toxicity or infections by blood and/or stool cultures, cytomegalovirus infection by antigenemia assay, or a reduced dose of the suspect drug.

Endoscopic findings have been gradually staged according to the classification proposed by Cruz-Correa (12) (Fig. 1): stage 0: normal; stage I: loss of vascular pattern and/or focal moderate erythema; stage II: edema and/or diffuse moderate erythema; stage III: edema, erythema, erosions and/or bleeding; stage IV: ulceration, exudates and/or bleeding.

In the histological analysis, the presence of apoptotic bodies was considered to be “compatible with GVHD”. The histological findings have been gradually staged according to the classification proposed by McDonald and Sales (13) in 1984: grade 0: normal; grade I: single cell necrosis (apoptosis) noted on medium power; grade II: evidence of epithelial damage by crypt/glandular abscesses, epithelial flattening or glandular/crypt dilation; grade III: dropout of one or more crypts/glands, grade IV: total epithelial denudation.

In the descriptive analysis of the sample, percentages were used for qualitative variables, and measures of central tendency (mean and/or median if there was great asymmetry or dispersion) and dispersion (standard deviation) for quantitative variables. We used SPSS v. 15.0 (Chicago, Illinois, USA) for those calculations. All dichotomous variables were analyzed with $\chi^2$ test in contingency tables in order to compare the distribution of categorical variables, as well as Fisher’s exact test and Monte Carlo simulations. A 95% confidence interval for the odds ratio was used, and the continuous and categorical variables were analyzed with ANOVA test and we used the Pearson’s r correlation coefficient.

RESULTS

Baseline characteristics of the study group and endoscopic and histological findings are summarized in table I.

Endoscopic diagnosis of GVHD

Three hundred thirty eight endoscopies of the upper gastrointestinal tract were performed in 197 patients with suspect diagnosis of acute or chronic GVHD; macroscopic endoscopic data compatible with GVHD were present in only 83 patients with GVHD (34.2%). On the other hand, in patients without histological and clinical confirmation of GVHD, the 35.3% (n = 30) showed an endoscopy compatible with GVHD. Endoscopic findings to the diagnosis of GVHD have a sensitivity (S) of 34%, specificity levels (SP) of 65%, a positive predictive value (PPV) of 73% and a negative predictive value (NPV) of 48%.

Endoscopic findings in patients with GVHD according to the classification of endoscopic severity –Cruz-Correa (12) classification– were not related with clinical severity.
**Table I. Baseline characteristics of the study group and endoscopic and histological findings**

<table>
<thead>
<tr>
<th>Patients, n</th>
<th>197</th>
</tr>
</thead>
<tbody>
<tr>
<td>Men, n (%)</td>
<td>119 (60.2)</td>
</tr>
<tr>
<td>Women, n (%)</td>
<td>78 (39.8)</td>
</tr>
<tr>
<td>Mean age, years (standard deviation)</td>
<td>45.3 (14)</td>
</tr>
<tr>
<td>Endoscopic studies, n</td>
<td>379</td>
</tr>
<tr>
<td>Gastroscopies, n (%)</td>
<td>338 (89.2)</td>
</tr>
<tr>
<td>First 100 days</td>
<td>223 (66)</td>
</tr>
<tr>
<td>GVHD, patients n (%)</td>
<td>135 (68.5)</td>
</tr>
<tr>
<td>Acute GI GVHD, n (%)</td>
<td>98 (49.7)</td>
</tr>
<tr>
<td>Mild</td>
<td>24 (24.5)</td>
</tr>
<tr>
<td>Moderate</td>
<td>56 (57.1)</td>
</tr>
<tr>
<td>Severe</td>
<td>18 (18.4)</td>
</tr>
<tr>
<td>Chronic GI GVHD, n (%)</td>
<td>90 (45.6)</td>
</tr>
<tr>
<td>Mild</td>
<td>29 (32.2)</td>
</tr>
<tr>
<td>Moderate</td>
<td>46 (51.1)</td>
</tr>
<tr>
<td>Severe</td>
<td>14 (15.6)</td>
</tr>
<tr>
<td>Acute and chronic GI GVHD, n (%)</td>
<td>53 (26.9)</td>
</tr>
</tbody>
</table>

**Endoscopic grading of severity, n (%)**

| Grade 0 | 160 (65.8) |
| Grade I | 34 (14) |
| Grade II | 21 (8.6) |
| Grade III | 20 (8.2) |
| Grade IV | 8 (3.3) |

**Histological grade in patients with acute GI GVHD, n(%)**

| Grade I | 48 (48) |
| Grade II | 29 (29.6) |
| Grade III | 18 (18.4) |
| Grade IV | 0 |

*According to the classification proposed by Cruz-Correa (12). **According to the classification proposed by McDonald and Sales (13).

**Complications**

Digestive bleeding after the biopsy has been registered as a complication, with an incidence of 2% (n = 4). In three of these cases, they were mild, and in one case, it was moderate bleeding which required endoscopic techniques in order to be controlled.

**DISCUSSION**

**GVHD and endoscopy**

Gut GVHD is a frequent complication after allogeneic SCT; more than 50% of the patients will be sent to the endoscopic room in order to confirm this clinical diagnosis. Although histological confirmation is needed to establish the diagnosis, macroscopic diagnosis is crucial in order to begin the treatment on the day of the endoscopy.

Our results show that diagnostic based only on endoscopic findings is poor, with a high percentage of false positives and negatives and it were not related to the clinical severity of GVHD. In a retrospective study in which patients with GVHD suspect underwent gastroscopy and biopsy (11), no differences were found with regard to the endoscopic findings or the symptoms among the patients that were later diagnosed with gastrointestinal GVHD and those who were not diagnosed with that condition. In this study, 18% of the patients with histological results compatible with GVHD presented normal endoscopic results.

The best gastrointestinal site to take a biopsy is unknown (14). The most logical approach would be to take a biopsy of a certain area according to the predominant symptoms (15). Thomson et al. (14) carried out a prospective study with 24 patients in 2006, in which they combined gastroscopy (taking gastric and duodenal biopsies), colonoscopy (biopsies of left and right colon) and ileoscopy (biopsy of terminal ileum) in transplanted patients who suffered diarrhea over the first 100 days after the transplant. They obtained a higher diagnostic yield with biopsies of the left colon (82%), compared with 77% in biopsies of the right colon, 68% in the ileum, 65% in the duodenum and 71% in the antrum. The combination of colonoscopy plus ileoscopy and colonoscopy plus gastroscopy showed the highest percentages of positive biopsies (95 and 94%, respectively).

In 2008, Ross et al. conducted a prospective study with 112 patients who simultaneously underwent a biopsy of the stomach, the duodenum and the rectosigmoid colon for the diagnosis of gastrointestinal GVHD and obtained that rectosigmoid biopsies revealed the highest levels of diagnostic yield for GVHD with regard to sensitivity, specificity, PPV and NPV, compared with all other locations (95.6, 100, 100 and 84%, respectively). The sensitivity of gastric and duodenal biopsies was 72.5% (p < 0.00001) and 79.2% (p = 0.0018), respectively, while NPV was 45.6% for the stomach (p = 0.0039) and 52.5% (p = 0.02) for the duodenum (7).

**Histology**

Biopsy was performed in 331 out of the 338 upper endoscopies (98%). The esophagus was biopsied in 19 explorations (7.8%), the stomach in 324 (92.2%) and the duodenum in 18 (7.4%). Stomach biopsies had a sensitivity of 89%, specificity of 30.6%, PPV of 63.8%, and NPV of 67%. In the esophagus, S = 33.3%, SP = 100%, PPV = 100%, and NPV = 41%, and in duodenum S = 80%, SP = 62.5%, PPV = 57%, and NPV = 83.3%. When all locations were united, S = 85.6% SP = 34.6% PPV = 64.2%, and NPV = 63.7%.

Histological severity was significantly associated with clinical severity (p = 0.018) with a Pearson’s r correlation of 0.24 (p = 0.006).

Histological severity was not related to the endoscopic findings —according to the Cruz-Correa (12) classification—.
Our results are similar to these, with a global sensitivity of 85.6%, but with a low NPV (63.7%).

GVHD and histology

The anatomopathological interpretation of stages I and II in the postoperative period is not without difficulties (16). First of all, the histological changes secondary to pre-transplant therapy for cyto-reduction may imitate GVHD. These changes that are secondary to a drug-related toxicity usually take place over the first 20 days after transplantation, although there have been described cases after the 30th day (17,18). Infections in the post-transplantation period (bacterial, fungal, parasitic and viral) are also a problem, because they can produce signs and symptoms that are similar to GVHD, especially cytomegalovirus infections (19).

Cheung et al. (20) published a retrospective study in 2008 in which they compared the endoscopic findings and the histological ones from 101 patients. The endoscopic findings revealed a significantly positive statistical relation with histological abnormalities (OR = 33.6; 95% CI: 4.3-261.1).

In 1994, a study found a gradual difference from 0 to 1 between the histological and the endoscopic (macroscopic) classifications of acute GVHD in 87.6% of endoscopies (21). However, a more recent study (14) found a difference from 2 to 4 stages in 28.2% of biopsies compared with the endoscopic assessment. In this study, a histological diagnosis of acute GVHD was obtained in 44.7% of the biopsies of endoscopically normal areas, which highlights the need of performing biopsies in areas with seemingly normal mucosa. These authors consider that the histopathological stage is not useful in the assessment of the severity of GVHD in transplanted patients, and they assert that the predictive factors for response and mortality in GVHD should be established after the clinical severity criteria. In our study, 65.8% of patients with GVHD had a normal endoscopy.

On the other hand, a recent study with 27 patients with GVHD (determined via colon biopsies) has shown that histological stages III and IV, compared with stages I and II, do not only present more intense symptoms (p = 0.01), but also require second-line treatments due to corticoid refractoriness (p = 0.027), and they present a higher mortality associated to GVHD complications (p = 0.05) (22). These data are compatible with our results, because we obtain a positive correlation between histological stages and clinical severity (Pearson’s r = 0.24; p = 0.006), but fail to achieve this correlation with endoscopic involvement.

We conclude that upper endoscopy is useful for the diagnosis of GVHD, allowing the taking of biopsies that can ultimately lead to the diagnosis, but with limited accuracy because the histological findings have low sensitivity and specificity, while the endoscopic findings are usually non-specific. It is necessary to perform biopsies of apparently normal mucosa areas because a high percentage of histological diagnosis is obtained.

REFERENCES